Published in J Biol Chem on May 06, 2013
Extracellular Vesicles Present in Human Ovarian Tumor Microenvironments Induce a Phosphatidylserine-Dependent Arrest in the T-cell Signaling Cascade. Cancer Immunol Res (2015) 0.83
Immunogenicity of subcutaneously administered therapeutic proteins--a mechanistic perspective. AAPS J (2013) 0.82
A Novel Platform for Immune Tolerance Induction in Hemophilia A Mice. Mol Ther (2017) 0.81
Phosphatidylserine Converts Immunogenic Recombinant Human Acid Alpha-Glucosidase to a Tolerogenic Form in a Mouse Model of Pompe Disease. J Pharm Sci (2016) 0.75
Intravenous administration of Factor VIII-O-Phospho-L-Serine (OPLS) complex reduces immunogenicity and preserves pharmacokinetics of the therapeutic protein. Eur J Pharm Sci (2014) 0.75
Effect of Biophysical Properties of Phosphatidylserine Particle on Immune Tolerance Induction Toward Factor VIII in a Hemophilia A Mouse Model. J Pharm Sci (2016) 0.75
Dendritic cells and the control of immunity. Nature (1998) 56.54
Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity (2005) 23.00
Tolerogenic dendritic cells. Annu Rev Immunol (2001) 13.77
Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity (2006) 5.91
Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev (2009) 3.56
CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol (2004) 3.36
Natural and TGF-beta-induced Foxp3(+)CD4(+) CD25(+) regulatory T cells are not mirror images of each other. Trends Immunol (2008) 2.50
The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost (1995) 2.25
How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol (2010) 2.11
Rituximab in the treatment of acquired factor VIII inhibitors. Blood (2002) 1.99
TGF-beta and regulatory T cell in immunity and autoimmunity. J Clin Immunol (2008) 1.49
Cytokine-conditioned dendritic cells induce humoral tolerance to protein therapy in mice. Hum Gene Ther (2012) 1.44
Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex. J Biol Chem (2005) 1.39
Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A. J Pharm Sci (2008) 1.21
The molecular mechanisms of immunomodulation and tolerance induction to factor VIII. J Thromb Haemost (2009) 1.09
Factor VIII inhibitors. Adv Exp Med Biol (2001) 1.02
Effect of B-cell depletion using anti-CD20 therapy on inhibitory antibody formation to human FVIII in hemophilia A mice. Blood (2010) 0.98
Phosphatidylserine reduces immune response against human recombinant Factor VIII in Hemophilia A mice by regulation of dendritic cell function. Clin Immunol (2010) 0.90
Suppression of the immune response to FVIII in hemophilia A mice by transgene modified tolerogenic dendritic cells. Mol Ther (2011) 0.85
Gene therapy for tolerance and vice versa: a case for hemophilia. Curr Opin Mol Ther (2010) 0.83
Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron (2004) 4.21
The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci U S A (2006) 3.30
Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci U S A (2010) 2.34
A clustered plasticity model of long-term memory engrams. Nat Rev Neurosci (2006) 2.06
Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells. J Immunol (2007) 1.94
Delivery of therapeutic proteins. J Pharm Sci (2010) 1.58
Tsx produces a long noncoding RNA and has general functions in the germline, stem cells, and brain. PLoS Genet (2011) 1.37
Follicular lymphoma intratumoral CD4+CD25+GITR+ regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8+CD25- and CD4+CD25- T cells. J Immunol (2007) 1.33
Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis. PLoS One (2011) 1.33
A presenilin-1 mutation identified in familial Alzheimer disease with cotton wool plaques causes a nearly complete loss of gamma-secretase activity. J Biol Chem (2010) 1.28
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. J Immunol (2008) 1.24
Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A. J Pharm Sci (2008) 1.21
Characterization of age-dependent and progressive cortical neuronal degeneration in presenilin conditional mutant mice. PLoS One (2010) 1.10
IL-12 reverses anergy to T cell receptor triggering in human lung tumor-associated memory T cells. Clin Immunol (2005) 1.09
Trans-dominant negative effects of pathogenic PSEN1 mutations on γ-secretase activity and Aβ production. J Neurosci (2013) 1.08
Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. Pharm Res (2011) 1.04
Indirect regulation of presenilins in CREB-mediated transcription. J Biol Chem (2009) 1.03
Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice. AAPS J (2010) 0.97
Human CD4+ effector memory T cells persisting in the microenvironment of lung cancer xenografts are activated by local delivery of IL-12 to proliferate, produce IFN-gamma, and eradicate tumor cells. J Immunol (2005) 0.95
Phospholipid binding improves plasma survival of factor VIII. Thromb Haemost (2010) 0.92
Familial frontotemporal dementia-associated presenilin-1 c.548G>T mutation causes decreased mRNA expression and reduced presenilin function in knock-in mice. J Neurosci (2012) 0.92
Membrane-associated TGF-beta1 inhibits human memory T cell signaling in malignant and nonmalignant inflammatory microenvironments. J Immunol (2006) 0.91
T cells and stromal fibroblasts in human tumor microenvironments represent potential therapeutic targets. Cancer Microenviron (2010) 0.91
Human CD4+ T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-gamma. J Immunol (2003) 0.90
Phosphatidylserine reduces immune response against human recombinant Factor VIII in Hemophilia A mice by regulation of dendritic cell function. Clin Immunol (2010) 0.90
Reciprocal functional modulation of the activation of T lymphocytes and fibroblasts derived from human solid tumors. J Immunol (2010) 0.89
Downregulation of CD40 signal and induction of TGF-β by phosphatidylinositol mediates reduction in immunogenicity against recombinant human Factor VIII. J Pharm Sci (2011) 0.89
IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments. Clin Immunol (2009) 0.89
Human ovarian tumor ascites fluids rapidly and reversibly inhibit T cell receptor-induced NF-κB and NFAT signaling in tumor-associated T cells. Cancer Immun (2013) 0.89
Effect of route of administration of human recombinant factor VIII on its immunogenicity in Hemophilia A mice. J Pharm Sci (2009) 0.88
Tumor vaccination with cytokine-encapsulated microspheres. Methods Mol Med (2003) 0.88
PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia A mice. AAPS J (2011) 0.87
CTLA-4 blockade augments human T lymphocyte-mediated suppression of lung tumor xenografts in SCID mice. Cancer Immunol Immunother (2005) 0.86
Passive transfer of polyethylene glycol to liposomal-recombinant human FVIII enhances its efficacy in a murine model for hemophilia A. J Pharm Sci (2008) 0.86
Application of fluorescence spectroscopy to quantify shear-induced protein conformation change. Biophys J (2009) 0.86
Germ line tumor-associated immunoglobulin VH region peptides provoke a tumor-specific immune response without altering the response potential of normal B cells. Blood (2004) 0.85
Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII. AAPS J (2009) 0.84
In vitro immunogenicity risk assessment of therapeutic proteins in preclinical setting. Methods Mol Biol (2011) 0.84
Memory T cells in human tumor and chronic inflammatory microenvironments: sleeping beauties re-awakened by a cytokine kiss. Immunol Invest (2006) 0.84
Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a mice. J Pharm Sci (2012) 0.84
Human CD4+ effector T cells mediate indirect interleukin-12- and interferon-gamma-dependent suppression of autologous HLA-negative lung tumor xenografts in severe combined immunodeficient mice. Cancer Res (2002) 0.83
Changes in ovarian tumor cell number, tumor vasculature, and T cell function monitored in vivo using a novel xenograft model. Cancer Immun (2013) 0.82
Immunogenicity of subcutaneously administered therapeutic proteins--a mechanistic perspective. AAPS J (2013) 0.82
Behavioral deficits, early gliosis, dysmyelination and synaptic dysfunction in a mouse model of mucolipidosis IV. Acta Neuropathol Commun (2014) 0.82
Targeting the TCR signaling checkpoint: a therapeutic strategy to reactivate memory T cells in the tumor microenvironment. Expert Opin Ther Targets (2008) 0.81
Human nasal polyp microenvironment maintained in viable and functional states as xenografts in SCID mice. Ann Otol Rhinol Laryngol (2006) 0.81
O-phospho-L-serine, multi-functional excipient for B domain deleted recombinant factor VIII. AAPS J (2007) 0.80
Influence of route of administration and liposomal encapsulation on blood and lymph node exposure to the protein VEGF-C156S. J Pharm Sci (2011) 0.80
Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice. J Pharm Sci (2014) 0.79
Nonlinear pharmacokinetics of factor VIII and its phosphatidylinositol lipidic complex in hemophilia A mice. Biopharm Drug Dispos (2014) 0.79
Allometry of factor VIII and informed scaling of next-generation therapeutic proteins. J Pharm Sci (2013) 0.78
Physicochemical properties of epidermal growth factor receptor inhibitors and development of a nanoliposomal formulation of gefitinib. J Pharm Sci (2012) 0.78
Memory T cells in the chronic inflammatory microenvironment of nasal polyposis are hyporesponsive to signaling through the T cell receptor. J Assoc Res Otolaryngol (2012) 0.78
Phosphatidylinositol induces fluid phase formation and packing defects in phosphatidylcholine model membranes. Chem Phys Lipids (2011) 0.78
Effects of hypertonic buffer composition on lymph node uptake and bioavailability of rituximab, after subcutaneous administration. Biopharm Drug Dispos (2014) 0.78
Use of a folding model and in situ spectroscopic techniques for rational formulation development and stability testing of monoclonal antibody therapeutics. J Pharm Sci (2010) 0.78
O-phospho-l-serine mediates hyporesponsiveness toward FVIII in hemophilia A-murine model by inducing tolerogenic properties in dendritic cells. J Pharm Sci (2014) 0.77
Development and characterization of lipidic cochleate containing recombinant factor VIII. Biochim Biophys Acta (2007) 0.77
Human nasal polyp microenvironments maintained in a viable and functional state as xenografts in NOD-scid IL2rgamma(null) mice. Ann Otol Rhinol Laryngol (2009) 0.77
B cell tumor vaccine enhanced by covalent attachment of immunoglobulin to surface proteins on dendritic cells. Clin Immunol (2005) 0.76
Folding considerations for therapeutic protein formulations. Prog Mol Biol Transl Sci (2008) 0.76
Anatomical, physiological, and experimental factors affecting the bioavailability of sc-administered large biotherapeutics. J Pharm Sci (2014) 0.75
Effects of replacement of factor VIII amino acids Asp519 and Glu665 with Val on plasma survival and efficacy in vivo. AAPS J (2014) 0.75
Liposome-mediated cytokine gene delivery to human tumor xenografts. Methods Enzymol (2003) 0.75